Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus recently hosted a virtual panel discussion focused on advancing gender equity for women in science, attended by over 150 participants. The session, part of the Model-Informed Drug Development (MIDD+) conference, featured a diverse group of speakers emphasizing the importance of male involvement in the conversation. Jill Fiedler-Kelly, President of Cognigen, highlighted the need for policy changes to support women, including flexible hours and parental leave. Current statistics show that 52% of Simulations Plus scientists are women, but more work is needed for equity, particularly for women of color in STEM. The panel emphasized creating supportive environments and critically examining existing policies.
Simulations Plus (NASDAQ: SLP) has partnered with the Sino-American Cancer Foundation to enhance drug discovery focused on the MTHFD2 target, a key area in cancer treatment. This collaboration will utilize Simulations Plus’ Artificial Intelligence-driven Drug Design technology and ADMET Predictor® software to develop novel inhibitors. The initiative includes creating quantitative structure-activity relationship (QSAR) models and optimizing lead compounds for efficacy. The SACF will provide funding and support throughout the project, expected to yield valuable compounds for cancer therapy.
Simulations Plus (NASDAQ: SLP) will announce its financial results for the second quarter of fiscal year 2023 on April 5, 2023, after the market closes. The company has been a leader in the biosimulation market for over 25 years, providing software and consulting services to drug discovery and development sectors. Interested stakeholders can listen to the conference call at 5 p.m. EDT on the same day, with access via a live webcast or phone call. For more information about the company's services and initiatives, visit their official website.
Simulations Plus, Inc. (Nasdaq: SLP) has announced that CEO Shawn O’Connor will present at the Sidoti Small-Cap Investor Conference, scheduled for March 22-23, 2023. O’Connor's presentation is set for March 23, 2023, at 3:15 p.m. Eastern Time. The live webcast can be accessed via provided links and will be available for replay afterward. Simulations Plus is a leading provider of software and consulting services in the biosimulation market, supporting various pharmaceutical processes for over 25 years. For further details about the conference, visit the Sidoti website or contact Brian Siegel from Hayden IR.
Simulations Plus (Nasdaq: SLP) announced a collaborative research agreement with the Institute of Medical Biology at the Polish Academy of Sciences. This partnership aims to design new compounds targeting the RORγ/RORγT nuclear receptors using AI and machine learning through the ADMET Predictor® platform. The collaboration involves jointly owning intellectual property resulting from this research, which focuses on treating cancers associated with these receptors. The project combines expertise from both organizations to optimize drug design, enhancing opportunities for new compound development.
Simulations Plus (NASDAQ: SLP) announced the release of MonolixSuite™ version 2023R1, featuring significant upgrades to the PKanalix, Monolix, and Simulx modules. This update enhances user data input, report generation, and plotting flexibility, improving performance and interoperability. President Jonathan Chauvin emphasized the integration of user feedback for a more streamlined modeling experience. A webinar on the new features will take place on March 16, 2023, at 12:00 p.m. ET. Simulations Plus continues to serve the pharmaceutical industry with innovative biosimulation solutions.
Simulations Plus, Inc. (Nasdaq: SLP), a prominent provider of simulation software for pharmaceuticals, announced its participation in Oppenheimer’s 33rd Annual Healthcare Conference, held virtually from March 13-15, 2023. CEO Shawn O’Connor will present on March 14, 2023, at 11:20 a.m. Eastern Time, and he will engage with investors throughout the day. A live webcast of the presentation can be accessed via their website and will be available for replay afterward.
Simulations Plus, Inc. (NASDAQ: SLP), a leader in modeling software for pharmaceutical safety, will present at the Raymond James 44th Annual Institutional Investors Conference from March 5-8, 2023, in Orlando, Florida. CEO Shawn O’Connor is scheduled to speak on March 7, 2023, at 1:40 p.m. Eastern Time and will host one-on-one meetings. Interested parties can access a live webcast and presentation on the company's Investors page post-event. Attendance is by invitation only. Simulations Plus has been serving the biosimulation market for over 25 years, offering solutions for drug discovery and regulatory submissions.
Simulations Plus (Nasdaq: SLP) has entered a new collaboration with a leading agrochemicals company to enhance the ADMET Predictor platform. This partnership aims to improve the accuracy of predicting ionization constants (pKa) for chemical compounds by utilizing the partner's proprietary data. Dr. Robert Fraczkiewicz highlighted that this collaboration will expand chemical coverage and drive next-generation safety assessments, particularly important due to global regulations limiting animal testing. The enhancements will benefit clients across multiple industries, including chemicals and cosmetics.
Simulations Plus (NASDAQ: SLP) has launched NAFLDsym v2B Beta, a new version of its quantitative systems pharmacology modeling software aimed at enhancing treatment development for nonalcoholic steatohepatitis (NASH). This release features a faster and more intuitive interface, developed using the Julia programming language, which significantly increases simulation speeds for large datasets. Key updates include a modern GUI, integration with the Julia toolkit, and a results viewer for previously exported files. A tech talk webinar on this release is scheduled for March 14, 2023, at 11:00 a.m. Eastern Time.